Skip to content

Clinical trials

Phase 2 Autoimmune Diseases trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Autoimmune Diseases Phase: Phase 2 Clear all

117 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20022
20032
20042
20056
20064
20071
20084
20092
20105
20116
20123
20135
20141
20153
20163
20175
20183
20194
202011
20218
20225
20234
20244
20257
20268

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed57
Recruiting18
Terminated17
Active, not recruiting11
Unknown status9
Not yet recruiting3
Withdrawn2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Heart, Lung, and Blood Institute (NHLBI)8
National Cancer Institute (NCI)6
Novartis Pharmaceuticals5
National Institute of Allergy and Infectious Diseases (NIAID)4
Assistance Publique - Hôpitaux de Paris3
Immunovant Sciences GmbH3
National Institute of Dental and Craniofacial Research (NIDCR)3
Amgen2
Anthera Pharmaceuticals2
AstraZeneca2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Autoimmune Diseases117
Immune System Diseases26
Lupus Erythematosus, Systemic15
Diabetes Mellitus, Type 114
Arthritis, Rheumatoid12
Sjogren's Syndrome9
Multiple Sclerosis8
Thrombocytopenia8
Anemia, Aplastic7
Connective Tissue Diseases7

Trials

Showing 51 to 75 of 117. Each trial links to its page on Pharma Observatory.

17 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.